# OnCo record paper-attard-abiraterone-phase-1-cyp17-jco-2008 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-attard-abiraterone-phase-1-cyp17-jco-2008" ;
schema:name "Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven"@en ;
schema:alternateName "Attard 2008 abiraterone phase 1"@en, "CYP17 inhibition abiraterone first-in-human"@en ;
schema:description "Twenty-one men whose prostate cancer had already stopped responding to every hormone treatment available were given a drug that shuts off the last remaining source of androgen. Two thirds had their PSA fall, which proved the cancer had never stopped depending on the hormone."@en ;
schema:url ;
schema:dateModified "2026-09-25"^^xsd:date ;
schema:citation , ;
onco:tag "prostate-evidence" ;
schema:sameAs ;
schema:datePublished "2008"^^xsd:gYear ;
schema:author "Attard G, Reid AH, Yap TA, et al." ;
onco:related , , , ;
onco:cancers , ;
onco:sections , ;
onco:targets ;
onco:drugs ;
onco:institutions , ;
onco:terms , ;
onco:people , ;
onco:bottlenecks , ;
onco:journals .